目的 探討雙歧桿菌聯(lián)合美沙拉嗪對潰瘍性結(jié)腸炎的療效觀察。方法 選取2008年1月—2018年1月于北京市豐臺區(qū)南苑醫(yī)院消化內(nèi)科診治的306例潰瘍性結(jié)腸炎患者，采用隨機數(shù)字法分為對照組和觀察組，每組各153例。對照組患者給予美沙拉嗪腸溶片，1.0 g/次，3次/d。觀察組患者在對照組基礎(chǔ)上聯(lián)合雙歧桿菌三聯(lián)活菌膠囊，2粒/次，2次/d。兩組患者均接受8周治療。比較兩組患者的臨床療效和不良反應發(fā)生率，并測定兩組治療前后Azzolini內(nèi)鏡評分、Mayo評分、C反應蛋白（CRP）、白介素-6（IL-6）、纖維蛋白原（FIB）及血小板計數(shù)（PLT）。結(jié)果 治療后，觀察組患者臨床治療有效率為90.20%，對照組有效率為75.16%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者的Azzolini內(nèi)鏡評分、Mayo評分、CRP、IL-6、FIB及PLT均顯著降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且觀察組患者的Azzolini內(nèi)鏡評分、Mayo評分、CRP、IL-6、FIB及PLT均顯著低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療期間，觀察組患者不良反應發(fā)生率為5.88%，對照組患者的不良反應發(fā)生率為3.92%，差異均無統(tǒng)計學意義。結(jié)論 雙歧桿菌三聯(lián)活菌膠囊聯(lián)合美沙拉嗪腸溶片能夠顯著改善潰瘍性結(jié)腸炎的臨床癥狀及凝血功能，并降低炎性反應，安全性較好。

Objective To investigate the clinical effect of bifidobacterium combined with mesalazine in treatment of ulcerative colitis. Methods Patients (306 cases) with ulcerative colitis in gastroenterology department of Beijing Nanyuan Hospital from January 2008 to January 2018 were divided into control group and observation group according to the random number method, and each group had 153 cases. Patients in the control group was given Mesalazine Enteric Coated Tablets, 1.0 g/time, three times daily. Patients in the observation group was given Bifidobacterium Triple Live Capsules on the basis of control group, 2 grains/time, twice daily. Patients in two groups were treated for 8 weeks. The clinical treatment effect and the incidence of the adverse reaction in two groups were compared, and the Azzolini endoscopic and Mayo scores, the levels of CRP, IL-6, FIB, and PLT in two groups before and after treatment were measured. Results After treatment, the effective rate of clinical effect in the observation group was 90.20%, the effective rate in the control group was 75.16%, the difference was statistically significant (P<0.05). After treatment, Azzolini endoscopy score, Mayo score, CRP, IL-6, FIB and PLT levels in two groups were significantly decreased, and there was significant difference before and after treatment in the same group (P<0.05). And the Azzolini endoscopic score, Mayo score, CRP, IL-6、FIB and PLT in the observation group were significantly lower than those in the control group, the difference was statistically significant (P<0.05). During the treatment, the incidence of the adverse drug reaction in the observation group was 5.88%, and the incidence of the adverse drug reaction in the control group was 3.92%, the differences were not statistically significant. Conclusion Bifidobacterium Triple Live Capsules combined with Mesalazine Enteric Coated Tablets in treatment of ulcerative colitis can siginificantly improved the clinical symptoms and coagulation function, and decreased the inflammatory reaction, with good safety.